Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prashanth Prithviraj

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|July 31, 2018
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular CarcinomaRitu Shrestha, Prashanth Prithviraj, Matthew Anaka, et al.
Scientific Reports|August 15, 2020
Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomesPrashanth Prithviraj, Matthew Anaka, Erik W Thompson, et al.
Journal of Clinical Medicine|June 2, 2021
Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot StudyLu Cao, Prashanth Prithviraj, Ritu Shrestha, et al.
Progress in Molecular Biology and Translational Science|September 12, 2024
Advances in CRISPR/Cas systems-based cell and gene therapyArpita Poddar, Farah Ahmady, Prashanth Prithviraj, et al.
Oncotarget|May 14, 2016
Identifying and targeting determinants of melanoma cellular invasionAparna Jayachandran, Prashanth Prithviraj, Pu-Han Lo, et al.
BMC Cancer|February 25, 2016
Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cellsAparna Jayachandran, Pu-Han Lo, Anderly C Chueh, et al.
Oncotarget|July 23, 2014
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanomaAparna Jayachandran, Matthew Anaka, Prashanth Prithviraj, et al.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Oncology|July 31, 2018
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular CarcinomaRitu Shrestha, Prashanth Prithviraj, Matthew Anaka, et al.
Scientific Reports|August 15, 2020
Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomesPrashanth Prithviraj, Matthew Anaka, Erik W Thompson, et al.
Journal of Clinical Medicine|June 2, 2021
Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot StudyLu Cao, Prashanth Prithviraj, Ritu Shrestha, et al.
Progress in Molecular Biology and Translational Science|September 12, 2024
Advances in CRISPR/Cas systems-based cell and gene therapyArpita Poddar, Farah Ahmady, Prashanth Prithviraj, et al.
Oncotarget|May 14, 2016
Identifying and targeting determinants of melanoma cellular invasionAparna Jayachandran, Prashanth Prithviraj, Pu-Han Lo, et al.
BMC Cancer|February 25, 2016
Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cellsAparna Jayachandran, Pu-Han Lo, Anderly C Chueh, et al.
Oncotarget|July 23, 2014
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanomaAparna Jayachandran, Matthew Anaka, Prashanth Prithviraj, et al.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Pageof 2